Effects of Air Pollution Exposure Reduction by Filter Mask on Heart Failure

NCT ID: NCT01960920

Last Updated: 2015-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Exposure to air pollution is associated with increase in cardiovascular morbidity and mortality. Controlled human exposure studies have demonstrated impaired vascular function and heart rate variability on healthy volunteers. The aim of this study is to investigate the effects of reducting diesel exhaust inhalation on endothelial function, heart rate variability and cardiopulmonary stress testing in healthy volunteers and patients with chronic heart failure, by using a filter mask.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Design and setting: Double-blind randomised crossover studies in a university teaching hospital

Patients: 30 patients with stable Heart Failure (NYHA I-III) and 15 healthy volunteers

Interventions: All 45 subjects will be exposed to dilute diesel exhaust (PM2.5 of 300 mg/m3), filtered diesel exhaust (filter mask), or filtered air

Main outcome measures: Endothelial function, heart rate variability, six-minute walking test and blood samples for inflammatory factors

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exposure to Pollution Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Volunteers

Dilute diesel exhaust Filtered diesel exhaust Filtered air

Group Type ACTIVE_COMPARATOR

Filtered diesel exhaust

Intervention Type OTHER

Mask-filtered exposure to diesel exhaust

Unfiltered diesel exhaust

Intervention Type OTHER

Diesel Exhaust Inhalation

Clean air

Intervention Type OTHER

No pollution and no filter mask

Heart Failure patients

Dilute diesel exhaust Filtered diesel exhaust Filtered air

Group Type EXPERIMENTAL

Filtered diesel exhaust

Intervention Type OTHER

Mask-filtered exposure to diesel exhaust

Unfiltered diesel exhaust

Intervention Type OTHER

Diesel Exhaust Inhalation

Clean air

Intervention Type OTHER

No pollution and no filter mask

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Filtered diesel exhaust

Mask-filtered exposure to diesel exhaust

Intervention Type OTHER

Unfiltered diesel exhaust

Diesel Exhaust Inhalation

Intervention Type OTHER

Clean air

No pollution and no filter mask

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Filter Mask 8812 (www.3m.com.br) Diesel Generator Toyama TD-2500 C, www.toyama.com.br

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* NYHA I-III;
* Left Ventricle Ejection Fraction \< 50%;
* Clinical condition stable for more than three months prior to the randomization;

Exclusion Criteria

* Severe arterial hypertension;
* Severe Pulmonary disease;
* Patients with pace-markers;
* Patients with constrictive pericarditis;
* Severe chronic kidney disease;
* Patients with pulmonary hypertension;
* Stroke within the last six months;
* Severe hepatic disease;
* Patients with musculoskeletal limitations to exercise;
* Patients with cardiac cachexia.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

Sponsor Role collaborator

LABORATÓRIO DE INSUFICIÊNCIA CARDÍACA E TRANSPLANTE INCOR/HCFMUSP

UNKNOWN

Sponsor Role collaborator

LABORATÓRIO DE POLUIÇÃO ATMOSFÉRICA EXPERIMENTAL (LPAE/ FMUSP).

UNKNOWN

Sponsor Role collaborator

InCor Heart Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jefferson Luis Vieira

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Edimar A Bocchi, pHD

Role: STUDY_CHAIR

Heart Failure Lab. Coordinator

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Failure Lab. Incor HCFMUSP

São Paulo, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

References

Explore related publications, articles, or registry entries linked to this study.

Vieira JL, Guimaraes GV, de Andre PA, Cruz FD, Saldiva PH, Bocchi EA. Respiratory Filter Reduces the Cardiovascular Effects Associated With Diesel Exhaust Exposure: A Randomized, Prospective, Double-Blind, Controlled Study of Heart Failure: The FILTER-HF Trial. JACC Heart Fail. 2016 Jan;4(1):55-64. doi: 10.1016/j.jchf.2015.07.018.

Reference Type DERIVED
PMID: 26738952 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010/50150-0

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

3439/10/028

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.